PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Assessment of pain • Treatment PART 05: Pipeline portfolio • Information on pipeline candidates PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by drug class • Opioids • NSAIDs • Other • Global opioids market • Global NSAIDs market PART 08: Market segmentation by type • Musculoskeletal pain • Surgical and trauma pain • Cancer pain • Neuropathic pain • Migraine pain • Obstetrical pain • Fibromyalgia pain • Burn pain • Dental/facial pain • Pediatric pain • Global musculoskeletal pain drugs market • Global surgical and trauma pain drugs market • Global cancer pain drugs market • Global neuropathic pain drugs market • Global migraine pain drugs market • Global obstetrical pain drugs market • Global fibromyalgia pain drugs market • Global burn pain drugs market • Global dental/facial pain drugs market • Global pediatric pain drugs market PART 09: Geographical segmentation • Pain management drugs market in Americas • Pain management drugs market in EMEA • Pain management drugs market in APAC PART 10: Market drivers • Rise in older population • Promising pipeline • Increase in awareness of pain management drugs • Favorable regulatory scenario PART 11: Impact of drivers PART 12: Market challenges • Generic competition • Adverse effects • Preference for alternative therapies • Short-term relief • Threat of counterfeit products PART 13: Impact of drivers and challenges PART 14: Market trends • Increase in R&D activities • Off-label drug usage • Strategic alliances PART 15: Vendor landscape • Competitive scenario • AstraZeneca • Endo International • Johnson & Johnson • Pfizer • Purdue Pharma • Other prominent vendors • List of abbreviations PART 16: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Pain assessment Exhibit 03: Types of pain scales Exhibit 04: Treatment options for pain Exhibit 05: Commonly used non-opioids for pain management Exhibit 06: Commonly used adjuvant medicines for pain Exhibit 07: Pain management Exhibit 08: Pipeline portfolio: Major drug candidates under development for pain management Exhibit 09: Global pain management drugs market 2015-2020 ($ billions) Exhibit 10: Five forces analysis Exhibit 11: Global pain management drugs market by drug class Exhibit 12: Segmentation of global pain management drugs market by drug class, 2015 Exhibit 13: Global opioids market 2015-2020 ($ billions) Exhibit 14: Key drivers and challenges of global opioids market Exhibit 15: Global NSAIDs market 2015-2020 ($ billions) Exhibit 16: Key drivers and challenges of global NSAIDs market Exhibit 17: Global pain management drugs market segmentation by type Exhibit 18: Global pain management drugs market segmentation 2015 Exhibit 19: Global musculoskeletal pain drugs market 2015-2020 ($ billions) Exhibit 20: Global surgical and trauma drugs market 2015-2020 ($ billions) Exhibit 21: Global cancer pain drugs market 2015-2020 ($ billions) Exhibit 22: Global neuropathic pain drugs market 2015-2020 ($ billions) Exhibit 23: Global migraine pain drugs market 2015-2020 ($ billions) Exhibit 24: Global obstetrical pain drugs market 2015-2020 ($ billions) Exhibit 25: Global fibromyalgia pain drugs market 2015-2020 ($ billions) Exhibit 26: Global burn pain drugs market 2015-2020 ($ billions) Exhibit 27: Global dental/facial pain drugs market 2015-2020 ($ billions) Exhibit 28: Global pediatric pain drugs market 2015-2020 ($ billions) Exhibit 29: Global pain management drugs market by type: YoY revenue and growth 2015-2020 Exhibit 30: Global pain management drugs market by geographical segmentation 2015 Exhibit 31: Global pain management drugs market revenue by geography 2015-2020 ($ billions) Exhibit 32: Pain management drugs market in Americas 2015-2020 ($ billions) Exhibit 33: Pain management drugs market in EMEA 2015-2020 ($ billions) Exhibit 34: Pain management drugs market in APAC 2015-2020 ($ billions) Exhibit 35: Global pain management drugs market: YoY revenue and growth based on geography 2015-2020 Exhibit 36: Impact of drivers Exhibit 37: Challenges in global pain management drugs market Exhibit 38: Impact of drivers and challenges Exhibit 39: Trends in global pain management drugs market Exhibit 40: AstraZeneca: Key pain products segmentation by revenue 2014 Exhibit 41: AstraZeneca: YoY growth rate and revenue of Vimovo 2012-2014 ($ millions) Exhibit 42: AstraZeneca: Key takeaways Exhibit 43: Endo International: YoY growth rate and revenue of Opana ER 2012-2014 ($ millions) Exhibit 44: Endo International: YoY growth rate and revenue of Voltaren 2012-2014 ($ millions) Exhibit 45: Endo International: YoY growth rate and revenue of Lidoderm 2012-2014 ($ millions) Exhibit 46: Endo International: YoY growth rate and revenue of Percocet 2012-2014 ($ millions) Exhibit 47: Endo International: Key takeaways Exhibit 48: Johnson & Johnson: Key takeaways Exhibit 49: Pfizer: YoY growth rate and revenue of Lyrica 2012-2014 ($ billions) Exhibit 50: Pfizer: YoY growth rate and revenue of Celebrex 2012-2014 ($ billions) Exhibit 51: YoY growth rate and revenue of Relpax 2012-2014 ($ millions) Exhibit 52: Pfizer: Key takeaways Exhibit 53: Purdue Pharma: Key takeaways

AstraZeneca, Endo International, Johnson & Johnson, Pfizer, Purdue Pharma, Allergan, AstraZeneca, Baxter, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Durect, GlaxoSmithKline, Hospira, Merck, Novartis, Pain Therapeutics, F. Hoffmann-La Roche, Sanofi, UCB, Valeant, Taro Pharmaceuticals, Achelios Therapeutics, Alder Biopharmace-uticals, Amgen, CoLucid, Daiichi Sankyo, Dr. Reddy's Laboratories, Eli Lilly, GW Pharmaceuticals, Immune Pharmaceuticals, Innovative Med Concepts, NeurAxon, OptiNose, RedHill, Sorrento Therapeutics, SUDA, Teva, Tonix, Trigemina, WEX Pharmaceuticals, Zynerba Pharmaceuticals.